COVID-19 Serology Assays: To Test or Not to Test

June 2, 2020

Sponsored Content

The usage of serology-based COVID-19 antibody testing can help us understand the level and prevalence of COVID-19 in communities. Are these tests the ultimate answer? Live: Tuesday, Jun. 2, 2020 at 11am EDT On demand available after airing until Jun. 2, 2021. Register free

Register free: http://www.appliedclinicaltrialsonline.com/act_w/serology_assays

Event Overview
In the past 6 months, we have been severely impacted by the COVID-19 pandemic. An unprecedented global effort has taken place to fight COVID-19 and reduce its impact. Healthcare professionals have been at the frontline of this initiative with the support of public and private sectors.

Recent research has greatly increased our knowledge of COVID-19 and the physiopathology of its infection. Public Health and Regulatory Authorities, policy makers and governments are rapidly adapting to mitigate the risk of COVID-19. In Vitro Diagnostic (IVD) device manufacturers have produced serology tests detecting the presence of antibodies to SARS-COV-2 virus. The use of these tests to drive decisions regarding coping with and reacting to the COVID-19 pandemic is now under consideration. Are these tests the ultimate answer?

3 Key Takeaways:

  • Overview of the immune response to SARS-CoV-2/COVID-19 infection

  • How serology tests can estimate COVID-19 exposure in the general population and possibly provide a “certificate of immunity”

  • Results and interpretations from serology tests that will support drug development

SpeakerDr. Patrice Hugo, Chief Scientific Officer, Q Squared Solutions

Time and date: Tuesday, Jun. 2, 2020 at 11am EDT

On demand available after airing until Jun. 2, 2021.

Sponsor: Q2 Solutions

Register free: http://www.appliedclinicaltrialsonline.com/act_w/serology_assays

Related Content:

Webcasts